- Home
- CRF vs RCUS Comparison
CRF vs RCUS Comparison
Compare CRF & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRF
- RCUS
- Stock Information
- Founded
- CRF 1973
- RCUS 2015
- Country
- CRF United States
- RCUS United States
- Employees
- CRF N/A
- RCUS N/A
- Industry
- CRF Finance/Investors Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- CRF Finance
- RCUS Health Care
- Exchange
- CRF Nasdaq
- RCUS Nasdaq
- Market Cap
- CRF 836.6M
- RCUS 906.4M
- IPO Year
- CRF N/A
- RCUS 2018
- Fundamental
- Price
- CRF $7.93
- RCUS $8.47
- Analyst Decision
- CRF
- RCUS Buy
- Analyst Count
- CRF 0
- RCUS 9
- Target Price
- CRF N/A
- RCUS $20.86
- AVG Volume (30 Days)
- CRF 1.1M
- RCUS 1.1M
- Earning Date
- CRF 01-01-0001
- RCUS 08-07-2025
- Dividend Yield
- CRF 18.10%
- RCUS N/A
- EPS Growth
- CRF N/A
- RCUS N/A
- EPS
- CRF 1.40
- RCUS N/A
- Revenue
- CRF $11,461,786.00
- RCUS $141,000,000.00
- Revenue This Year
- CRF N/A
- RCUS N/A
- Revenue Next Year
- CRF N/A
- RCUS $28.73
- P/E Ratio
- CRF $5.38
- RCUS N/A
- Revenue Growth
- CRF 6.53
- RCUS N/A
- 52 Week Low
- CRF $5.70
- RCUS $6.50
- 52 Week High
- CRF $9.56
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- CRF 69.76
- RCUS 45.47
- Support Level
- CRF $7.38
- RCUS $7.92
- Resistance Level
- CRF $7.92
- RCUS $8.81
- Average True Range (ATR)
- CRF 0.09
- RCUS 0.45
- MACD
- CRF 0.02
- RCUS -0.06
- Stochastic Oscillator
- CRF 98.21
- RCUS 39.02
About CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.